Holen Sie sich die Stockscreener-App
71.70
0.38%
-0.27
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
Price to earnings forward of PTC Therapeutics, Inc. – BX:P91 - TradingView
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal - MarketBeat
The week in pharma: action, reaction and insight – week to August 14, 2026 - thepharmaletter.com
Assenagon Asset Management S.A. Has $563,000 Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Is Maintained at Overweight by Barclays - moomoo.com
Walleye Capital LLC Takes $1.59 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity' - Sahm
PTCT Maintained by Barclays -- Price Target Raised to $122 - GuruFocus
PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy - MedCity News
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $130 - moomoo.com
PTC takes a chance on Sangamo’s Fabry disease gene therapy - BioPharma Dive
PTCT Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $109 - GuruFocus
PTC to Acquire Sangamo’s Fabry Disease Gene Therapy - Contract Pharma
PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy - TipRanks
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale - BioSpace
Form 8K PTC Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
PTC to expand rare disease portfolio with ST-920 buy - thepharmaletter.com
PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction - Endpoints News
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
Bankrupt Sangamo scores at least $163 million in asset sale, which had two big winners - The Business Journals
PTC Therapeutics to acquire Fabry disease gene therapy ST-920 - Investing.com
PTC Therapeutics to acquire Fabry disease gene therapy ST-920 By Investing.com - Investing.com India
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program - PR Newswire
How Ptc Therapeutics Inc. (PTCT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Why PTC Therapeutics (PTCT) Is Up 6.7% After Profit Beat, Higher Guidance And New Board Appointment - simplywall.st
Is PTC Therapeutics (PTCT) Undervalued As Profit And Revenue Guidance Jumped? - Sahm
Don't Ignore The Insider Selling In PTC Therapeutics - moomoo.com
Have PTC Therapeutics Insiders Been Selling Stock? - simplywall.st
Zacks Research Downgrades PTC Therapeutics (NASDAQ:PTCT) to Hold - MarketBeat
PTC Therapeutics Inc (PTCT) Stock News Today - TradingKey
PTC Therapeutics CEO Klein sells $705,722 in company stock By Investing.com - Investing.com South Africa
PTC Therapeutics Inc (PTCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PTC Therapeutics CEO Klein sells $705,722 in company stock - Investing.com
Bank of America Corp DE Raises Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT Stock Position Lifted by California State Teachers Retirement System - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells 10,292 Shares of Stock - MarketBeat
PTC Therapeutics (PTCT) CEO sells 10,292 shares to cover taxes - Stock Titan
PTC Therapeutics (PTCT) Stock Fair Value Edges Higher After Analyst Target Increases - finance.yahoo.com
PTCT Therapeutics (PTCT) insider to sell 10,292 vested shares under Rule 144 - Stock Titan
PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - finance.yahoo.com
PTC Therapeutics, Inc. (PTCT) Stock Analysis: A 43.66% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Barclays Keeps Their Buy Rating on PTC Therapeutics (PTCT) - The Globe and Mail
Defilade Capital Management L.P. Invests $25.63 Million in PTC Therapeutics, Inc. $PTCT - marketbeat.com
Empowered Funds LLC Sells 192,506 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
Sei Investments Co. Raises Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Upgraded to "Strong-Buy" at Wall Street Zen - MarketBeat
First Trust Advisors LP Decreases Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. Stock 12‑Month Price Target Raised to $97.86, Implies 30% Upside - TradingView
PTC Therapeutics Falls Despite Strong Q2 Results as Investors Weigh One-Time Boosts and Legacy Product Pressure - Quiver Quantitative
PTC Therapeutics, Inc. Stock 12‑Month Price Target Raised to $96.93, Implies 28% Upside - TradingView
PTC Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
PTC Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2026 - marketscreener.com
PTC Therapeutics 2Q 2026: Revenue $360.5M, EPS $0.92— 10-Q Summary - TradingView
PTC Therapeutics stock jumps 5% after topping Q2 estimates on strong Sephience sales - Investing.com
PTC Therapeutics: Q2 Earnings Snapshot - KING5.com
PTC Therapeutics (NASDAQ:PTCT) Posts Quarterly Earnings Results, Beats Expectations By $0.68 EPS - MarketBeat
PTC Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
PTC Therapeutics, Inc. (NASDAQ:PTCT) Short Interest Update - MarketBeat
PTC Therapeutics (PTCT) Receives a Hold from RBC Capital - The Globe and Mail
PTC Therapeutics, Inc. (PTCT) Stock Analysis: Evaluating a 26.74% Potential Upside Amidst Volatile Revenue Growth - DirectorsTalk Interviews
PTC Therapeutics, Inc. $PTCT Shares Bought by Rock Springs Capital Management LP - MarketBeat
PTCT|PTC Therapeutics Inc|Price:75.790|Chg%:-1.030 - TradingKey
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):